{"entity":{"id":"mahtas-malaysia","kind":"institution","name":"Malaysian Health Technology Assessment Section (MaHTAS)","aka":["MaHTAS","Cawangan Penilaian Teknologi Kesihatan"],"tldr":"The health technology assessment unit of Malaysia's Ministry of Health. It assesses new medicines, devices and procedures, writes the national clinical practice guidelines and scans for emerging technologies.","summary":"MaHTAS sits in the Medical Development Division of the Ministry of Health and describes itself as the ministry's custodian of evidence- and value-based medicine. It produces health technology assessment reports on drugs, biologics, devices, equipment, procedures and programmes, assessing effectiveness, safety, cost-effectiveness and organisational, social and ethical issues; it coordinates the development of clinical practice guidelines; and it runs horizon scanning for emerging technologies.\n\nThe National Strategic Plan for Cancer Control Programme 2021-2025 reports that the ministry's HTA unit assessed low-dose CT for lung cancer screening in 2017 and, because the test had high sensitivity but low specificity in high-risk people, recommended it only in a research setting; Malaysia has no national lung screening programme. The plan also describes value-based medicine as the ministry's route to deciding whether a new therapy is used in its hospitals.\n\nOnCo found no published cost-effectiveness threshold for Malaysia. The coordinates are a Putrajaya centroid; the section's address was not read.","asOf":"2026-11-04","links":[{"label":"MaHTAS: Info korporat","url":"https://mymahtas.moh.gov.my/index.php/about-us/info-korporat"},{"label":"Ministry of Health: National Strategic Plan for Cancer Control Programme 2021-2025, section on screening (PDF)","url":"https://www.iccp-portal.org/system/files/plans/National_Strategic_Plan_for_Cancer_Control_Programme_2021-2025.pdf"}],"tags":[],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ministry-of-health-malaysia","npra-malaysia","institut-kanser-negara"],"pathways":[],"terms":["hta"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Putrajaya","country":"MY","lat":2.926,"lng":101.696,"institutionType":"government","website":"https://mymahtas.moh.gov.my","programs":["Health technology assessment reports","Clinical practice guidelines","Horizon scanning"]},"route":"/institutions/mahtas-malaysia/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"institution":[{"id":"institut-kanser-negara","kind":"institution","name":"Institut Kanser Negara (National Cancer Institute, Malaysia)","route":"/institutions/institut-kanser-negara/"},{"id":"ministry-of-health-malaysia","kind":"institution","name":"Ministry of Health Malaysia","route":"/institutions/ministry-of-health-malaysia/"},{"id":"npra-malaysia","kind":"institution","name":"National Pharmaceutical Regulatory Agency (NPRA), Malaysia","route":"/institutions/npra-malaysia/"}],"term":[{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"}]}}